Study aid only. Verify against current guidelines, primary literature, staging manuals, and prescribing information before clinical use.

← All algorithms  ·  Related notes →

Oropharynx SCC (p16/HPV+) — Definitive Treatment

Oropharynx SCC p16 / HPV + Early T0–2 N0–1 (single node ≤3 cm) Resection + selective neck dissection Definitive RT Clinical trial Locally advanced T1–2 N2–3 · T3–4 any N Definitive concurrent chemoRT (cisplatin) TORS + neck dissection ± adjuvant Adjuvant therapy by pathologic risk No adverse features observe Extranodal extension ± positive margin chemoRT (cisplatin) or RT Positive margin re-resect or chemoRT Other risk features RT or chemoRT Intermediate-risk (selected) de-escalate RT to 50 Gy — ECOG 3311